Grant List
Represents Grant table in the DB
GET /v1/grants?page%5Bnumber%5D=1385&sort=award_id
{ "links": { "first": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1&sort=award_id", "last": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1424&sort=award_id", "next": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1386&sort=award_id", "prev": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1384&sort=award_id" }, "data": [ { "type": "Grant", "id": "6676", "attributes": { "award_id": "5U19AI149504-03", "title": "Modulation of repopulation of anti HIV-1 gene-modified cells to enhance efficacy and safety", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2020-05-07", "end_date": "2025-04-30", "award_amount": 448040, "principal_investigator": { "id": 22355, "first_name": "Dong Sung SUNG", "last_name": "An", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 818, "ror": "", "name": "UNIVERSITY OF CALIFORNIA LOS ANGELES", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 818, "ror": "", "name": "UNIVERSITY OF CALIFORNIA LOS ANGELES", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true }, "abstract": "Project 3: Summary/Abstract The overall goal of Project 3 is to modulate the levels of anti-HIV-1 chimeric antigen receptor (CAR) and broadly neutralizing antibodies (bNAb) modified immune cells by developing the most effective and safe positive and negative selection strategy to (1) achieve a therapeutic level of repopulation and (2) incorporate a safety “kill-switch” to eliminate the genetically engineered anti-HIV-1 immune effector cells in cases of unexpected adverse effects, such as cytokine storm, autoimmune reaction and malignant transformation. The hematopoietic stem cell-based gene therapy approach has shown great promise to achieve an HIV-1 cure. However, one of the major limitations has been the difficulty of achieving the engraftment levels sufficient to provide therapeutic efficacy, in particular for HIV-1 infected patients where intensive myeloablative conditionings would be an unfavorable risk-benefit. Thus, a safe and titratable positive selection strategy is highly desirable to maximize the level of anti-HIV-1 gene engineered immune cells to treat patients with HIV-1 without dangerous intensive myeloablation. Furthermore, it is important to incorporate a safety “kill-switch” procedure to eliminate the genetically engineered anti-HIV-1 immune effector cells based on lessons learned from severe adverse effects in cancer immunotherapy. Therefore, we will develop a negative selection strategy as a safety “kill-switch” to eliminate genetically engineered immune cells. We will identify the most effective and safe selection strategy from (1) knocking down hypoxanthine-guanine phosphoribosyltransferase (HPRT) expression using RNA interference that enables us to effectively enrich or eliminate anti-HIV-1 gene-modified HSPC using clinically available prodrug 6-thioguanine or methotrexate, (2) co-expressing truncated non-functional human epidermal growth factor receptor (huEGFRt), a cell surface marker for a rapid ex vivo positive selection and in vivo negative selection by an FDA-approved anti-EGFR monoclonal antibody Cetuximab (Erbitux) and (3) the P140K mutant form of human O6-methylguanine-DNA-methyltransferase (MGMTP140K) for a positive selection. We hypothesize that a clinically relevant, safe and effective positive and negative selection strategy can be developed by rigorously evaluating our proposed selection strategies for our anti-HIV-1 CAR and scFv-Fc bNAb combining therapies to achieve a cure of HIV disease.", "keywords": [ "Adverse effects", "Antigens", "Autoimmune", "B-Lymphocytes", "Benefits and Risks", "Bone Marrow Purging", "CAR T cell therapy", "CD19 gene", "Cell Count", "Cell surface", "Cells", "Cellular Immunity", "Cetuximab", "Clinical", "Clinical Trials", "Collaborations", "Comparative Study", "Dangerousness", "Disease", "Effector Cell", "Engineered Gene", "Engraftment", "Epidermal Growth Factor Receptor", "Erbitux", "FDA approved", "Gene Delivery", "Gene-Modified", "Genetic Engineering", "Goals", "HIV", "HIV-1", "Hematopoietic stem cells", "Human", "Humoral Immunities", "Hypoxanthine Phosphoribosyltransferase", "Immune", "In Vitro", "Investigational New Drug Application", "Lentivirus Vector", "MGMT gene", "Macaca nemestrina", "Malignant - descriptor", "Malignant Neoplasms", "Methotrexate", "Modeling", "Mus", "Patients", "Procedures", "Prodrugs", "RNA Interference", "Reaction", "Risk", "Safety", "T-Lymphocyte", "Testing", "Therapeutic", "Thioguanine", "TimeLine", "Toxic effect", "Transplantation", "Treatment Efficacy", "Virus Replication", "base", "cancer immunotherapy", "chimeric antigen receptor", "chimeric antigen receptor T cells", "clinically relevant", "cytokine release syndrome", "gene therapy", "immunoengineering", "immunogenicity", "in vivo", "knock-down", "mutant", "neutralizing antibody", "nonhuman primate", "preclinical development", "programs" ], "approved": true } }, { "type": "Grant", "id": "6937", "attributes": { "award_id": "5U19AI157797-02", "title": "Administrative Core", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2021-03-01", "end_date": "2026-02-28", "award_amount": 360857, "principal_investigator": { "id": 22786, "first_name": "SCOTT J.", "last_name": "HULTGREN", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 827, "ror": "", "name": "WASHINGTON UNIVERSITY", "address": "", "city": "", "state": "MO", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 827, "ror": "", "name": "WASHINGTON UNIVERSITY", "address": "", "city": "", "state": "MO", "zip": "", "country": "United States", "approved": true }, "abstract": "PROJECT SUMMARY/ ABSTRACT: COVID-19 exemplifies the dire consequences of being unprepared for the next health crisis. One looming crisis involves the insidious rise of antibiotic resistant bacterial infections, necessitating the research described in our U19 application entitled “Innovative strategies to combat antibiotic-resistant infections” in response to RFA-AI-20-001 (Combating Antibiotic-resistant Bacteria Interdisciplinary Research Units (CARBIRU)). Our proposal is leveraged to translate basic science into new types of antibiotic-sparing medicines for common infections in the United States as well as common hospital-acquired infections. This U19 application utilizes a multi-departmental, multi-institutional, and interdisciplinary group of highly motivated microbiology, cell biology/physiology, immunology and medicinal chemistry researchers to develop antibiotic-sparing therapeutics and compounds that are capable of: i) treating common infections; and/or ii) increasing sensitivity to the current arsenal of available antibiotics. The Administrative Core (AC) will be responsible for coordinating the activities and monitoring the progress of the three research projects and the two scientific cores to achieve the overall goals of the U19 program. To accomplish this, the AC Leader, with the help of an Executive Committee comprising of the Leaders of the Research Projects and Cores, will oversee and coordinate the activities of the members of the Projects and Cores by: i) fostering frequent interactions; ii) supporting the exchange of data, methodologies, and ideas; iii) facilitating interactions with institutional and outside experts to gain advice for better functioning of the overall program and for translation of the program's findings into therapeutics development; and iv) coordinating financial and scientific progress reporting to granting agency staff. In addition, the AC will coordinate active participation in the U19 to ensure its overall success.", "keywords": [ "Affinity", "Antibiotic Resistance", "Antibiotics", "Area", "Attention", "Bacteria", "Bacterial Adhesins", "Bacterial Antibiotic Resistance", "Bacterial Infections", "Basic Science", "Budgets", "COVID-19", "Cellular biology", "Centers for Disease Control and Prevention (U.S.)", "Clinical", "Collaborations", "Combating Antibiotic Resistant Bacteria", "Communication", "Communication Methods", "Development", "Doctor of Philosophy", "Electronic Mail", "Ensure", "Fostering", "Funding", "Goals", "Grant", "Guidelines", "Health", "Human", "Immunology", "Infection", "Institution", "Interdisciplinary Study", "International", "Journals", "Leadership", "Ligands", "Medicine", "Membrane", "Methodology", "Microbiology", "Monitor", "Monoclonal Antibodies", "Multi-Drug Resistance", "Nosocomial Infections", "Pathogenicity", "Peer Review", "Persons", "Pharmaceutical Chemistry", "Physiology", "Program Evaluation", "Progress Reports", "Publications", "Regulation", "Research", "Research Personnel", "Research Project Grants", "Resource Sharing", "Schedule", "Scientist", "Series", "Site Visit", "Teleconferences", "Therapeutic", "Translating", "Translations", "United States", "United States National Institutes of Health", "Wages", "antibiotic resistant infections", "combat", "data exchange", "design", "improved functioning", "individual responsibility", "innovation", "meetings", "member", "mimetics", "novel antibiotic class", "pathogen", "pathogenic bacteria", "prevent", "product development", "programs", "response", "small molecule inhibitor", "success", "therapeutic development" ], "approved": true } }, { "type": "Grant", "id": "6938", "attributes": { "award_id": "5U19AI157797-02", "title": "Development of anti-adhesin mAbs and high-affinity ligand mimetics to treat and prevent UTIs", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2021-03-01", "end_date": "2026-02-28", "award_amount": 360857, "principal_investigator": { "id": 22786, "first_name": "SCOTT J.", "last_name": "HULTGREN", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 827, "ror": "", "name": "WASHINGTON UNIVERSITY", "address": "", "city": "", "state": "MO", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 827, "ror": "", "name": "WASHINGTON UNIVERSITY", "address": "", "city": "", "state": "MO", "zip": "", "country": "United States", "approved": true }, "abstract": "PROJECT SUMMARY/ABSTRACT: The climate surrounding COVID-19 has dramatically reminded us of the dire consequences of being unprepared for health crises. One looming health crisis is the surge of antibiotic-resistant bacterial infections that are no longer sensitive to our life saving antibiotic arsenal. Thus, this project is leveraged to translate basic science into antibiotic-sparing medicines for one of the most common bacterial infections in the United States, urinary tract infections (UTIs), as well as the most common hospital-acquired infection, catheter-associated UTIs (CAUTIs). The strategy is to develop therapeutics that work equally well against carbapenem-resistant Enterobacteriaceae (CRE) and extended-spectrum beta-lactamase (ESBL) producing Enterobacteriaceae, including the cause of over 80% of community-acquired UTIs, uropathogenic Escherichia coli (UPEC). CAUTIs pose a significant challenge for healthcare globally. While UPEC causes 50% of CAUTI, other pathogens, including ESBL and CRE Klebsiella, multidrug resistant (MDR) Acinetobacter and Gram-positive Enterococcus including vancomycin resistant Enterococcus (VRE), cause a significant proportion of CAUTIs. These MDR pathogens express adhesive factors required for colonization and infection in different host habitats involved in acute and chronic/recurrent UTIs as well as in CAUTIs. Small molecules and monoclonal antibodies (mAbs) will be developed that will treat and prevent disease by blocking these critical host-pathogen interactions. By acting extracellularly, these antibiotic-sparing therapeutics will be recalcitrant to intracellular mechanisms of resistance and avoid a common obstacle of cell permeability in drug discovery of small molecules. UPEC, Klebsiella and Acinetobacter express chaperone usher pathway (CUP) pili tipped with adhesins: i) FimH, FmlH, YehD, UclD (UPEC); ii) FimH (Klebsiella) and iii) CupD (Acinetobacter). These adhesins are critical for colonization of the bladder (FimH), inflamed bladder and kidney (FmlH), gut (FimH, UclD and YehD) and catheters (FimH and CupD). Further, Enterococcus faecalis express EbpA-tipped sortase-assembled pili, which are critical in CAUTI. Glycomimetics have shown great promise in neutralizing CUP adhesins in vivo to treat disease. For example, mannosides which neutralize FimH function, are potent therapeutics for treating and preventing UTI, since FimH is required by UPEC to colonize the bladder. Validating the work in this proposal, a mannoside has been selected, in collaboration with GSK, to proceed into phase 1a/ab clinical trials in humans. Also, a FimH vaccine has completed Phase 1a/1b clinical trials. The use of mAbs has revolutionized treatments for cancer, inflammatory, and neuronal disorders. Therapeutic mAbs have not yet been fully harnessed for treating infectious diseases, perhaps due to the historic success of antibiotics. In this project, we will develop therapeutic mAb designed to prevent critical host-pathogen interactions by neutralizing the adhesins described above. The combined strategies have the potential to produce transformative antibiotic-sparing therapeutics that work equally well against and antibiotic-sensitive and resistant infections.", "keywords": [ "Acinetobacter", "Acute", "Adhesives", "Affinity", "Antibiotic Resistance", "Antibiotics", "Antibodies", "Antibody Therapy", "Bacteria", "Bacterial Adhesins", "Bacterial Antibiotic Resistance", "Bacterial Infections", "Basic Science", "Binding", "Bladder", "COVID-19", "Catheters", "Cell Wall", "Cells", "Centers for Disease Control and Prevention (U.S.)", "Chronic", "Chronic Cystitis", "Climate", "Clinical Treatment", "Clinical Trials", "Collaborations", "Communicable Diseases", "Development", "Disease", "Enterobacteriaceae", "Enterococcus", "Enterococcus faecalis", "Extended-spectrum β-lactamase", "Fibrinogen", "Funding", "Galactose", "Gastrointestinal tract structure", "Gram-Negative Bacteria", "Habitats", "Health", "Healthcare", "Human", "Implant", "In Vitro", "Infection", "Inflammatory", "Ingestion", "Invaded", "Kidney", "Klebsiella", "Klebsiella pneumoniae", "Knowledge", "Life", "Ligands", "Longevity", "Mannose", "Mannosides", "Medicine", "Microbial Biofilms", "Modeling", "Molecular Chaperones", "Monoclonal Antibodies", "Multidrug-resistant Acinetobacter", "Neurons", "Nosocomial Infections", "Oral", "Pathogenicity", "Pathway interactions", "Pectins", "Permeability", "Phase", "Phase Ia/Ib Clinical Trial", "Pilum", "Plants", "Pre-Clinical Model", "Privatization", "Recurrence", "Resistance", "Resistance profile", "Resources", "Savings", "Seeds", "Structure-Activity Relationship", "Surface", "Testing", "Therapeutic", "Therapeutic Monoclonal Antibodies", "Tissues", "Translating", "United States", "Urinary tract infection", "Uropathogen", "Uropathogenic E. coli", "Vaccines", "Vancomycin Resistance", "Vancomycin resistant enterococcus", "Work", "antibiotic resistant infections", "bacterial community", "cancer therapy", "candidate identification", "carbapenem-resistant Enterobacteriaceae", "catheter associated UTI", "combat", "community-acquired UTI", "design", "diabetic", "drug discovery", "drug resistant pathogen", "experimental study", "extracellular", "gastrointestinal", "global health", "glycomimetics", "gut colonization", "host colonization", "implantation", "in vivo", "innovation", "mimetics", "mouse model", "multi-drug resistant pathogen", "pathogen", "pressure", "prevent", "programs", "receptor", "residence", "resistance mechanism", "small molecule", "sortase", "success", "wound" ], "approved": true } }, { "type": "Grant", "id": "11607", "attributes": { "award_id": "5U19AI167899-02", "title": "Research Project 1 - The pregnancy ImmunOME", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2022-04-19", "end_date": "2027-03-31", "award_amount": 747949, "principal_investigator": { "id": 21683, "first_name": "Andrea Goldberg", "last_name": "Edlow", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 736, "ror": "https://ror.org/002pd6e78", "name": "Massachusetts General Hospital", "address": "", "city": "", "state": "MA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 210, "ror": "https://ror.org/042nb2s44", "name": "Massachusetts Institute of Technology", "address": "", "city": "", "state": "MA", "zip": "", "country": "United States", "approved": true }, "abstract": "Project 1: Summary The COVID-19 pandemic has revolutionized our ability to decode the rules of maternal immunity. There is a significant gap in knowledge regarding innate and adaptive immune responses over the course of pregnancy and how trimester-specific perturbations in the maternal immunological signature might manifest in attributable risk or benefit to the maternal-fetal dyad. The COVID-19 vaccines and their real-world use by pregnant women present a unique opportunity to define the baseline, trimester-specific immune signature, and to examine the maternal immune response after in vivo perturbation with both de novo (never before seen by the immune system) and recall (boosted responses such as influenza and pertussis) vaccines across the trimesters of pregnancy. In Project 1 in the Maternal ‘Omics to Maximize Immunity (MOMi) consortium, we propose to apply a multi-‘OMICs approach to deeply and comprehensively capture shifts in the maternal immune response before and after maternal immunization across pregnancy. We will profile maternal peripheral blood mononuclear cells, plasma, placental cell isolates, and stool from pre- and post-maternal vaccination, using single cell RNA-Seq (scRNA-Seq), Assay for Transposase-Accessible Chromatin with high-throughput sequencing (scATAC-Seq), Cellular Indexing of Transcriptomes and Epitopes by Sequencing (scCITE-Seq), proteomics, metabolomics, and metagenomics, and integrate all data through the Data Management and Analysis Core (DMAC). In collaboration with Project 2, the ultimate goal is to define maternal immunity longitudinally across pregnancy trimesters in the normal baseline and vaccinated state, in order to build the most comprehensive Pregnancy Immune Atlas of innate and adaptive immune profiling across the maternal-fetal dyad. We will examine how the cellular transcriptome, microbiome, metabolome, and proteome shifts over the course of pregnancy, and how they are modified in response to different vaccine platforms (mRNA, adenovirus, adjuvanted protein) and types (de novo versus recall), providing a unique opportunity to profile the maternal immune response with unprecedented resolution. This detailed map of pregnancy immunity will generate critical data to open previously unrecognized therapeutic windows in this unusual and understudied area of human immunology.", "keywords": [ "Address", "Adenoviruses", "Adjuvant", "Age", "Antigens", "Area", "Atlases", "Biological Assay", "Body mass index", "COVID-19 pandemic", "COVID-19 vaccination", "COVID-19 vaccine", "Cell Separation", "Cells", "Cellular Assay", "Cellular Indexing of Transcriptomes and Epitopes by Sequencing", "Characteristics", "Child", "Chromatin", "Clinical", "Collaborations", "Complex", "Data", "Data Analyses", "Disease", "Enrollment", "Ensure", "Equilibrium", "Fc Receptor", "Feces", "Future", "Goals", "High-Throughput Nucleotide Sequencing", "Human", "Immune", "Immune Tolerance", "Immune response", "Immune system", "Immunity", "Immunologics", "Immunology", "In Vitro", "Infant", "Infection", "Inflammation", "Influenza", "Infrastructure", "Innate Immune Response", "Knowledge", "Maps", "Maternal Mortality", "Maternally-Acquired Immunity", "Messenger RNA", "Metabolic Diseases", "Metagenomics", "Mothers", "Peripheral Blood Mononuclear Cell", "Pertussis", "Pertussis Vaccine", "Plasma", "Population", "Pregnancy", "Pregnancy Trimesters", "Pregnant Women", "Proliferating", "Proteins", "Proteome", "Proteomics", "Recording of previous events", "Research Project Grants", "Resolution", "Risk", "SARS-CoV-2 negative", "Sampling", "Shapes", "Shotguns", "Systems Biology", "Therapeutic", "Time", "Transposase", "Vaccinated", "Vaccination", "Vaccine Design", "Vaccines", "Woman", "Work", "adaptive immune response", "antibody transfer", "booster vaccine", "cell type", "cohort", "data integration", "data management", "early pregnancy", "emerging pathogen", "experimental study", "fetal", "gut microbiome", "healthy pregnancy", "high dimensionality", "in vivo", "influenza virus vaccine", "insight", "maternal immune system", "maternal vaccination", "metabolome", "metabolomics", "metagenomic sequencing", "microbial", "microbiome", "multidisciplinary", "neonate", "next generation", "novel", "pandemic disease", "pathogen", "placental transfer", "prospective", "receptor expression", "response", "sex", "single-cell RNA sequencing", "therapeutic development", "transcriptome", "vaccine development", "vaccine platform", "vaccine response", "vaccine strategy" ], "approved": true } }, { "type": "Grant", "id": "11663", "attributes": { "award_id": "5U19AI167903-02", "title": "Systems biological assessment of B cell responses to vaccination", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2022-03-07", "end_date": "2027-02-28", "award_amount": 409240, "principal_investigator": { "id": 23528, "first_name": "Scott Dexter", "last_name": "Boyd", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 266, "ror": "https://ror.org/00f54p054", "name": "Stanford University", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 266, "ror": "https://ror.org/00f54p054", "name": "Stanford University", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true }, "abstract": "– Project 3 The focus of Project 3 is to study antigen-specific B cell and plasma cell responses in the context of two timely and fundamental topics in vaccinology: (i) Immunology of COVID-19 vaccines, and (ii) the impact of the microbiota on immune responses to vaccination. The COVID-19 pandemic caused by the novel coronavirus SARS-CoV-2 (CoV-2), and the vaccines developed to combat this pathogen, have underscored a need for greater understanding of primary antibody responses in humans. We will use a systematic panel of cutting- edge humoral immunity analyses to thoroughly characterize antibodies elicited by two CoV-2 vaccines, and the B cell and plasma cell clonal populations required for B cell memory and sustained antibody titers. Our focus will be on the serological, B cell and plasma cell responses elicited by a lipid nanoparticle mRNA vaccine (Pfizer-BioNTech), and a Matrix M-adjuvanted recombinant protein vaccine (Novavax). Combining these analyses with studies of innate immunity (Project 1) and T cell (Project 2) responses to these vaccines should highlight cellular mechanisms correlated with the strength and durability of antibody responses. Rare serious anaphylactoid adverse reactions have been reported for mRNA vaccines, particularly in individuals with a history of food allergy, and those with IgG antibodies specific for polyethylene glycol (PEG). We will examine potential B cell contributions to these anaphylactoid reactions, using specimens from affected individuals who received SARS-COV-2 mRNA vaccines. Finally, we will address the role of the microbiome on humoral immunity to vaccination, with a similar strategy of serological, memory B cell and plasma cell analyses in participants with or without temporarily ablated microbiota following antibiotic treatment. Of particular importance in the aforementioned studies, we will not only analyze peripheral blood B cells and plasmablasts, but also monitor lymph node germinal center reactions by fine-needle aspiration, and sample bone marrow plasma cells in the same participants, to comprehensively study humoral immunity to vaccination in humans. The combined impact of these investigations will likely be clinically significant in guiding the development of future vaccination strategies by uncovering the B cell and plasma cell specificities, differentiation pathways, and longevity stimulated by new SARS-CoV-2 vaccine platforms, and in clarifying the role of the microbiome in vaccine responses to novel antigens.", "keywords": [ "2019-nCoV", "Ablation", "Acute", "Address", "Adjuvant", "Adverse reactions", "Affect", "Affinity", "Allergic", "Antibiotic Therapy", "Antibiotics", "Antibodies", "Antibody Response", "Antibody titer measurement", "Antigens", "Avidity", "B-Cell Antigen Receptor", "B-Lymphocytes", "B-cell receptor repertoire sequencing", "Basophils", "Binding", "Biological Assay", "Blood", "Bone Marrow", "COVID-19", "COVID-19 pandemic", "COVID-19 vaccine", "Cells", "Clinical", "Clone Cells", "Collaborations", "DNA", "Data Analyses", "Development", "Ensure", "Epitopes", "Fine needle aspiration biopsy", "Food Hypersensitivity", "Future", "Glycoproteins", "Human", "Humoral Immunities", "Immune response", "Immunity", "Immunoglobulin G", "Immunoglobulin M", "Immunology", "Individual", "Infection", "Investigation", "Label", "Longevity", "Measures", "Memory B-Lymphocyte", "Methods", "Monitor", "Monoclonal Antibodies", "Natural Immunity", "Participant", "Pathogenicity", "Pathway interactions", "Phenotype", "Plasma Cells", "Plasmablast", "Polyethylene Glycols", "Population", "RNA vaccination", "RNA vaccine", "Rabies", "Rabies Vaccines", "Reaction", "Recombinant Proteins", "Recording of previous events", "Reporting", "Role", "SARS-CoV-2 antigen", "Sampling", "Serology", "Shapes", "Specificity", "Specimen", "Structure of germinal center of lymph node", "T-Lymphocyte", "Vaccination", "Vaccinee", "Vaccines", "Variant", "Viral", "Virus", "Virus Diseases", "adaptive immunity", "biological systems", "clinically significant", "combat", "coronavirus disease", "data management", "in vitro Assay", "lipid nanoparticle", "lymph nodes", "microbiome", "microbiota", "monoclonal antibody production", "multiplex assay", "novel", "novel coronavirus", "pathogen", "peripheral blood", "recruit", "response", "transcriptome", "vaccination strategy", "vaccine development", "vaccine platform", "vaccine response", "vaccinology", "variants of concern" ], "approved": true } }, { "type": "Grant", "id": "11667", "attributes": { "award_id": "5U19AI168631-02", "title": "Viral Immunity and VAccination (VIVA) Human Immunology Project Consortium (HIPC)", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 8224, "first_name": "Kentner L.", "last_name": "Singleton", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-03-22", "end_date": "2027-02-28", "award_amount": 2265730, "principal_investigator": { "id": 21760, "first_name": "Ana", "last_name": "Fernandez-Sesma", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 625, "ror": "https://ror.org/04a9tmd77", "name": "Icahn School of Medicine at Mount Sinai", "address": "", "city": "", "state": "NY", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [ { "id": 7185, "first_name": "Viviana A", "last_name": "Simon", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 625, "ror": "https://ror.org/04a9tmd77", "name": "Icahn School of Medicine at Mount Sinai", "address": "", "city": "", "state": "NY", "zip": "", "country": "United States", "approved": true }, "abstract": "The Viral Immunity and Vaccination (VIVA) Human Immunology Project Consortium (HIPC) will carry out a comprehensive systems immunology program to assess the dynamic human immune response to SARS-CoV- 2, seasonal influenza viruses and tetravalent and trivalent dengue vaccines and subsequent infections by those pathogens. It will generate comprehensive innate, cellular and adaptive immune signatures that correlate with vaccine outcomes. The VIVA HIPC will leverage recent advances in human immune profiling methods to characterize the diverse states of the human immune system before and after vaccination against these viral pathogens of great public health concern using novel immune phenotyping and genomics strategies that generate data and tools to be used for downstream data analysis and functional investigations. The proposed studies will use longitudinal biospecimens from established human cohorts of respiratory infections and vaccinations in the US and Argentina as well as from vaccine trials in the US (provided by the Clinical Core, Core B). In addition, validation experiments using human tonsils sourced from healthy individuals and exposed ex vivo to the different vaccine types will be conducted. Three complementary, well-integrated projects will produce in-depth human immune profiles and signatures of SARS-CoV-2 vaccinations and infections (Project 1), seasonal influenza vaccinations and infections (Project 2) as well as dengue vaccine and human challenge studies (Project 3). Unique in our approach is the use of longitudinal cohorts for in vivo profiling, supported by ex vivo human tonsillar histoculture (HC) models for infection and vaccination. Our holistic approach will provide cutting- responses to vaccinations and infections by the Immune Phenotyping Core (Core C), genomics/transcriptomics, including scRNAseq, CITEseq and spatial tissue transcriptomics by the Genomics Core (Core D), and experimental vaccinations in primary human tonsillar histocultures (HC) in Projects 1, 2 and 3. Data mining, bioinformatics to identify the network components and infer their interactions and correlations important for vaccine outcomes will be done by the Data management and Analysis Core (Core E). The VIVA HIPC will make the data, analyses and immune profiles generated available to the scientific community by coupling our local data infrastructure to ImmPort (directly or through the HIPC Coordinating Center). This integration will ensure full and timely release of clinical, sample, and experimental metadata in synchrony with genomic data releases to standard data repositories including SRA, GEO, and Genbank (Core E). The VIVA team (Drs. Krammer, Garcia-Sastre, Durbin, Gamarnik, van Bakel and Sebra) led by Dr. Fernandez-Sesma and Dr. Simon includes physicians, physician scientists and scientists with complementary expertise in viral immunology, viral pathogenesis, vaccinology, genomics, data analysis and a proven track record of collaboration and excellence.", "keywords": [ "2019-nCoV", "Area", "Argentina", "Bioinformatics", "Biological Assay", "Biological Models", "COVID-19 vaccination", "COVID-19 vaccine", "Cells", "Cellular Indexing of Transcriptomes and Epitopes by Sequencing", "Characteristics", "Classification", "Clinical", "Clinical Trials", "Collaborations", "Communicable Diseases", "Communities", "Coupling", "Cryopreserved Cell", "Data", "Data Analyses", "Data Set", "Dengue", "Dengue Vaccine", "Dengue Virus", "Development", "Differentiation Antigens", "Ensure", "Enzyme-Linked Immunosorbent Assay", "Epidemic", "Flow Cytometry", "Foundations", "Frequencies", "Genbank", "Generations", "Genes", "Genomic approach", "Genomics", "Goals", "Human", "Immune", "Immune response", "Immune system", "Immunity", "Immunization", "Immunoglobulins", "Immunologic Memory", "Immunologics", "Immunology", "Individual", "Infection", "Influenza A virus", "Influenza B Virus", "Influenza vaccination", "Innate Immune Response", "Investigation", "Learning", "Longitudinal cohort", "Lymphoid Tissue", "Maintenance", "Maps", "Measures", "Mediating", "Metadata", "Methods", "Modeling", "Morbidity - disease rate", "Pathway interactions", "Peripheral Blood Mononuclear Cell", "Phenotype", "Physicians", "Physiological", "Plasma", "Population", "Population Characteristics", "Prevention strategy", "Public Health", "Qualifying", "Research Personnel", "Respiratory Tract Infections", "SARS coronavirus", "Sampling", "Scientist", "Seasons", "Serology", "Serotyping", "Source", "Standardization", "System", "Techniques", "Technology", "Testing", "Tissues", "Tonsil", "Vaccinated", "Vaccination", "Vaccinee", "Vaccines", "Validation", "Viral", "Viral Antigens", "Viral Pathogenesis", "Virus", "Virus Diseases", "World Health", "adaptive immune response", "adaptive immunity", "cell type", "cohort", "data infrastructure", "data management", "data mining", "data repository", "data standards", "experimental study", "genomic data", "holistic approach", "human disease", "immunological status", "in vivo", "influenza infection", "influenzavirus", "live attenuated influenza vaccine", "mortality", "mosquito-borne", "network models", "next generation", "novel", "pandemic disease", "pathogen", "pathogenic virus", "phenotypic data", "predictive modeling", "programs", "response", "seasonal influenza", "sequencing platform", "tool", "transcriptomics", "vaccination outcome", "vaccine candidate", "vaccine immuno" ], "approved": true } }, { "type": "Grant", "id": "11668", "attributes": { "award_id": "5U19AI168631-02", "title": "Immune Phenotyping Core", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2022-03-22", "end_date": "2027-02-28", "award_amount": 522189, "principal_investigator": { "id": 21760, "first_name": "Ana", "last_name": "Fernandez-Sesma", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 625, "ror": "https://ror.org/04a9tmd77", "name": "Icahn School of Medicine at Mount Sinai", "address": "", "city": "", "state": "NY", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 625, "ror": "https://ror.org/04a9tmd77", "name": "Icahn School of Medicine at Mount Sinai", "address": "", "city": "", "state": "NY", "zip": "", "country": "United States", "approved": true }, "abstract": "The goal of the Immune Phenotyping Core (Core C) is to provide tools and reagents to the different projects that will be used to characterize the immune responses induced by vaccinations and infections with coronaviruses, influenza viruses and dengue viruses. The Core will leverage existing state-of-the-art serological techniques established in the Krammer laboratory, as well as multiplex analysis of cytokine and chemokine plasma profile and Cytek Aurora Spectral Flow Cytometry profiling of PBMCs and human tonsillar histocultures (HC) currently used and optimized in the Fernandez-Sesma laboratory. The following aims re proposed: Aim 1: Characterization of antibody responses to coronavirus, influenza virus and dengue virus vaccination and infection. The Core will provide assays, reagents and protocols to measure binding and functional antibody responses against SARS-CoV-2 for Project 1 and influenza viruses for Project 2. Additionally, the secretion of IgM, IgG and IgA in the supernatant of human tonsil histocultures (HC) treated with the different SARS-CoV-2 vaccines types (Project 1), influenza virus vaccines and viruses (Project 2) will be assessed. Aim 2: Characterization of cytokine/chemokine responses to coronavirus, influenza virus and dengue virus vaccination and infection. The Core will analyze the levels of cytokines and chemokines in the plasma of vaccinated/infected individuals and the supernatant of human tonsil histocultures treated with different vaccines for Projects 1, 2 and 3. Aim 3: Characterization of cellular responses to coronavirus, influenza virus and dengue virus vaccination and infection. Analysis of the cellular immune profiles of PBMCs from vaccinated/infected individuals over time, using Spectral Flow cytometry. Human tonsillar HC will be also analyzed by Cytek Aurora Spectral Flow Cytometry in order to capture early immune signatures and changes in cell populations corresponding to adaptive immune responses in those HC after treatment with different vaccines. We will obtain high-resolution data at the single-cell level to resolve the most challenging cell populations including cells expressing viral antigens. PBMCs will also be subjected to a complementary transcriptomics analysis by RNAseq conducted by the Genomics Core. These tools will serve to generate immune signatures representative of the longitudinal immune responses to vaccination and/or infection in study participants enrolled in observational non-interventional cohort studies in coordination with the Data Management and Analysis Core (Core E). Data obtained using these immunological techniques will be analyzed by the Data management and Analysis Core comparing them across the different systems used in the projects as well as in combination with the genomic data obtained in the Genomics Core (Core D) from the same samples. All data generated by the VIVA Projects and Cores, including the Immune Phenotyping Core, will be deposited by the Data Analysis Core into ImmPort.", "keywords": [ "2019-nCoV", "Aftercare", "Antibody Response", "Assessment tool", "Binding", "Biological Assay", "COVID-19 vaccine", "Cells", "Clinical", "Cohort Studies", "Collaborations", "Coronavirus", "Data", "Data Analyses", "Data Set", "Dengue Virus", "Deposition", "Enzyme-Linked Immunosorbent Assay", "Flow Cytometry", "Genomics", "Goals", "Human", "Immune", "Immune response", "Immunity", "Immunoglobulin A", "Immunoglobulin G", "Immunoglobulin M", "Immunologic Techniques", "Immunology", "Individual", "Infection", "Laboratories", "Letters", "Measures", "Mission", "Peripheral Blood Mononuclear Cell", "Phenotype", "Plasma", "Population", "Process", "Protocols documentation", "Reagent", "Resolution", "Sampling", "Serology", "Serum", "Services", "Standardization", "System", "Techniques", "Testing", "Time", "Tonsil", "Vaccinated", "Vaccination", "Vaccinee", "Vaccines", "Viral", "Viral Antigens", "Virus", "adaptive immune response", "base", "chemokine", "cytokine", "data management", "genomic data", "influenza virus vaccine", "influenzavirus", "instrument", "participant enrollment", "response", "tool", "transcriptome sequencing", "transcriptomics" ], "approved": true } }, { "type": "Grant", "id": "9284", "attributes": { "award_id": "5U19FD007100-02", "title": "Food Defense and Surveillance in Support of the FDA by the State Hygienic Laboratory at the University of Iowa", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [], "program_reference_codes": [], "program_officials": [ { "id": 25023, "first_name": "Laurie", "last_name": "Keppley", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2020-09-01", "end_date": "2025-06-30", "award_amount": 449991, "principal_investigator": { "id": 25024, "first_name": "Dustin", "last_name": "May", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 220, "ror": "https://ror.org/036jqmy94", "name": "University of Iowa", "address": "", "city": "", "state": "IA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 220, "ror": "https://ror.org/036jqmy94", "name": "University of Iowa", "address": "", "city": "", "state": "IA", "zip": "", "country": "United States", "approved": true }, "abstract": "- Overall: The culture of food safety that has been developed and sustained within the State Hygienic Laboratory (SHL) at the University of Iowa is a high-quality, performance-based effort that enhances public health, protects consumers, and promotes preparedness. The State Hygienic Laboratory has been engaged in maintaining quality systems in the laboratory in compliance with ISO/IEC 17025 since September 2013 and maintains AIHA Laboratory Accreditation specifically for the food scope by providing the resources - including systems, equipment, and personnel - to ensure adherence to rigorous QA/QC protocols and appropriate accrediting authority/agency standards. The aims of this overall application are to: 1) ensure laboratory capacity for the analysis of foods, 2) strengthen and enhance food response in urgent and emergency situations/outbreaks, and 3) enhance currently validated and potentially develop new analytical methods. The SHL management and technical staff supporting food safety have substantial experience in the public health laboratory. SHL chemists and microbiologists have performed food analysis for surveillance, outbreak and inspection samples since the early 2000s. SHL has all required and supplemental resources for full continuation of the food program in Iowa beyond the end of the FDA ISO 17025 and FDA FERN programs. SHL performs food operations in two lab locations. Within lab locations are BSL2 and BSL3 suites, biosafety cabinets, and fume hoods. Instrumentation includes ICPMS, LCMSMS, GCMSMS, IC, proportional counters, liquid scintillation counters, alpha and gamma spectrometers, thermocyclers, and substantial support equipment. AIHA program certificates for food, unique scopes, industrial hygiene and environmental lead are current for these locations. SHL is accredited by the National Environmental Laboratory Accreditation Program (NELAP) with oversight from the Oregon accrediting authority. SHL is supported by a LIMS developed and maintained in-house. A quality management system is in place and guided by the Quality Management Plan. Incorporated in the quality systems are a document control system (iPassport), a non-conforming event (NCE) protocol and a schedule of internal audits. Safety is addressed through substantial training and education requirements. There are improvements and new applications proposed that include expanded capability in Radiochemistry for rapid alpha-emitter screen, expanded capability in Chemistry for the analysis of juice and other sugary products and applying SHL's Microbiology validated in-house Cyclospora RT PCR assay to produce surveillance. In future years, SHL Microbiology plans to validate Endopep-MS procedure for C. botulinum toxin to replace discontinued ELISA toxin kits and particularly the mouse assay. In addition, the implications of COVID-19 on food and food surfaces is a critical emerging research area in virology testing that will need development for this aim relatively soon. SHL has the expertise, resources and facilities to contribute to that science, as well as all other projects that are proposed that will not only be a benefit SHL and Iowa, but also the FDA and FERN networks.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "6167", "attributes": { "award_id": "5U19MH113203-05", "title": "PRIDE SSA - Partnerships in Research to Implement and Disseminate Sustainable and Scalable Evidence Based Practices in sub-Saharan Africa", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Mental Health (NIMH)" ], "program_reference_codes": [], "program_officials": [ { "id": 20934, "first_name": "Holly R", "last_name": "Campbell-Rosen", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2017-05-01", "end_date": "2023-04-30", "award_amount": 1056811, "principal_investigator": { "id": 20935, "first_name": "Maria A", "last_name": "Oquendo", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 812, "ror": "", "name": "NEW YORK STATE PSYCHIATRIC INSTITUTE", "address": "", "city": "", "state": "NY", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [ { "id": 20936, "first_name": "MILTON L", "last_name": "WAINBERG", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 812, "ror": "", "name": "NEW YORK STATE PSYCHIATRIC INSTITUTE", "address": "", "city": "", "state": "NY", "zip": "", "country": "United States", "approved": true }, "abstract": "Global mental health (MH) treatment and research gaps require that efficacious treatments be scaled-up, leveraging existing platforms. In tandem, policies must sustain them over time. PRIDE SSA may generate templates for other LMICs by conducting a state of the art scale up study in Mozambique and by establishing a collaborative research network of nascent research “Seed Teams.” Such “Seed Teams,” trained by the capacity building component, may work across the region to build capacity and conduct implementation research to sustainably scale-up MH services. Scale Up Research (Mozambique) in MH and substance use disorders will evaluate strategies and costs of scaling up an innovative, integrated, sustainable, stepped-care community approach. We will leverage: (1) Mozambique's task-shifting strategy of training psychiatric technicians (PsyTs) to provide MH care, (2) the WHO-funded epilepsy community care program successfully implemented in 5 Provinces, now primed for scale-up by the Health Ministry. Our cost-effective approach redefines work roles without requiring new human resources. Importantly, it comports with the Health Ministry's plan to implement prevention and treatment for all MH conditions, rather than single disorders. The model employs EBPs (e.g. Psychopharmacology; Interpersonal Therapy), already in use by PsyTs to: a) establish a sustainable program delivered and supervised by non-MH professionals, overseen by MH specialists; b) provide community screening, care and/or referrals for all MH disorders; and c) use implementation tools to monitor sustainability. This collaborative network will scale-up a cost-effective, sustainable program and inform policy. Capacity Building Regional Partnerships will leverage well-established capacity building institutions (Foundation for Professional Development; U of Cambridge; U of Pretoria; Mozambique's Institute of Health Education and Research) and our Mozambique Fogarty/NIMH MH Implementation Program (partnership: Mozambique [Ministry of Health; U Eduardo Mondlane]; US [Columbia; U of Pennsylvania]; and Brazil [U Federal do São Paulo]) to train service providers, investigators and policy-makers from Botswana, Malawi, Mozambique, South Africa, Zambia. Each country will contribute `seed teams' committed to working together, that include all actors needed to develop, test, implement and sustain community based MH services using EBPs: 1) new researchers to conduct MH implementation and dissemination research; 2) policy makers to leverage evidence generated by local research to improve and test MH policies and programs; 3) trainer-of- trainers to prepare staff to deliver adapted EBPs that preserve fidelity; and 4) senior-level faculty to develop university programs to prepare the next generation of investigators. Training comprises synergistic didactics, hands-on research experience designed in partnership local stakeholders, and mentorship from local or US senior investigators. Lessons learned in the scale up research will be adapted for research in partner countries and other LMICs.", "keywords": [ "Adherence", "Africa South of the Sahara", "Botswana", "Brazil", "Caring", "Clinical", "Collaborations", "Communities", "Community Mental Health Services", "Consultations", "Country", "Development", "Diagnosis", "Diagnostic", "Disease", "Dissemination and Implementation", "Educational process of instructing", "Ensure", "Epilepsy", "Evidence based practice", "Faculty", "Foundations", "Funding", "Future Generations", "Goals", "Guidelines", "Health", "Health Personnel", "Health Policy", "Health Professional", "Health education", "Health system", "Healthcare", "Human Resources", "Institutes", "Institution", "International", "Intervention", "Knowledge", "Language", "Lead", "Malawi", "Mental Depression", "Mental Health", "Mental Health Services", "Mental Tests", "Mental disorders", "Mentorship", "Modeling", "Monitor", "Mozambique", "National Institute of Mental Health", "Outcome", "Pathway interactions", "Patients", "Pennsylvania", "Policies", "Policy Developments", "Policy Maker", "Policy Research", "Prevention", "Process", "Program Development", "Program Sustainability", "Province", "Psychopharmacology", "Public Health", "Research", "Research Methodology", "Research Personnel", "Research Project Grants", "Research Training", "Resources", "Role", "Schizophrenia", "Science", "Seeds", "Services", "South Africa", "Specialist", "Structure", "Substance Use Disorder", "Supervision", "System", "Testing", "Time", "Training", "Training Activity", "Training Programs", "United States Public Health Service", "Universities", "Work", "Zambia", "base", "care systems", "cost", "cost effective", "design", "dissemination research", "education research", "efficacious treatment", "experience", "hands on research", "health service use", "implementation research", "implementation tool", "improved", "innovation", "interpersonal therapy", "low and middle-income countries", "member", "neuropsychiatric disorder", "next generation", "preservation", "programs", "scale up", "screening", "service providers", "success", "systematic review", "treatment research", "user-friendly" ], "approved": true } }, { "type": "Grant", "id": "8605", "attributes": { "award_id": "5U24AI162625-02", "title": "Virus Taxonomy: A Community Knowledgebase Supporting Virus Research", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 21214, "first_name": "Liliana L.", "last_name": "Brown", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2021-08-03", "end_date": "2026-05-31", "award_amount": 594000, "principal_investigator": { "id": 24380, "first_name": "Elliot J.", "last_name": "Lefkowitz", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 612, "ror": "https://ror.org/008s83205", "name": "University of Alabama at Birmingham", "address": "", "city": "", "state": "AL", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 612, "ror": "https://ror.org/008s83205", "name": "University of Alabama at Birmingham", "address": "", "city": "", "state": "AL", "zip": "", "country": "United States", "approved": true }, "abstract": "Viruses are able to infect every kind of organism on the planet. They play an integral part in maintaining normal ecosystems but sometimes cause perturbations that have adverse impacts on human health, agriculture, and the wider environment. Understanding the role that viruses play in ecosystems and developing approaches to mitigate their undesirable effects represents a major goal of virologists. Organisms can only be understood in the context of their relationships. This begins with the delineation of common and distinguishing properties and is formalized by the science of taxonomy which creates an ordered, hierarchical system of classification and nomenclature. Taxonomy is critical for building a holistic understanding of the biology of the organisms that inhabit this planet. The International Committee on Taxonomy of Viruses (ICTV) provides a coherent framework for understanding viruses by classifying them on the basis of their kinships as described by the virus taxonomy. The ICTV taxonomic database and programs form the bedrock used by virologists worldwide to understand the global virome, standardize the nomenclature of the huge influx of newly discovered viruses, and promote both research and education in a rapidly changing environment. This proposal is aimed at expanding the effectiveness of the ICTV and strengthening its connections to a broad range of stakeholders. These include people involved in scientific, veterinary, medical, educational, and regulatory endeavors, and anyone else interested in viruses. Our aims focus on providing an integrated set of outcomes that modernized resources to ensure a stable, responsive, scalable infrastructure; increased availability and breadth of taxonomic and virological information; better tools to manage taxonomic classification and handling of data supporting high-throughput virus classification and curation; enhanced accessibility by individuals, groups, and information repositories; and outreach and training activities to ensure that the products of our efforts are used to benefit stakeholders and to promote better understanding of viruses and their classification. This work will advance the capacity of bench scientists, computer scientists, educators, trade regulators, pharmaceutical firms, government agencies, policy makers, and the general public to conduct leading edge research, mitigate the threat posed by viruses, and better understand the risks posed by viruses to human, animal, and agricultural health, and the planet’s ecology. This work will also contribute to national and international security by helping governments to respond to unforeseen outbreaks of virus diseases such as COVID-19.", "keywords": [ "2019-nCoV", "Acute", "Agriculture", "Animals", "Biological", "Biology", "COVID-19", "Classification", "Collection", "Communities", "Computer Systems", "Computers", "Custom", "Data", "Data Set", "Databases", "Development", "Disease", "Disease Outbreaks", "Ecology", "Ecosystem", "Education", "Education and Outreach", "Educational workshop", "Effectiveness", "Ensure", "Environment", "Funding", "General Population", "Generations", "Goals", "Government", "Government Agencies", "Health", "Health Sciences", "Human", "Individual", "Information Technology", "Infrastructure", "International", "Internet", "Knowledge", "Link", "Manuals", "Medical", "Mission", "Modernization", "National Security", "Nomenclature", "Online Systems", "Organism", "Outcome", "Persons", "Pharmacologic Substance", "Planets", "Play", "Policies", "Policy Maker", "Prevention", "Privatization", "Property", "Research", "Resources", "Risk", "Role", "Sampling", "Science", "Scientist", "Security", "Standardization", "Students", "System", "Taxonomy", "Testing", "Training", "Training Activity", "Training Programs", "Virus", "Virus Diseases", "Visual", "Work", "analytical tool", "base", "cloud based", "data access", "flexibility", "improved", "innovation", "interest", "interoperability", "knowledge base", "knowledge repository", "meetings", "novel", "open source", "outreach program", "programs", "repository", "response", "science and society", "social media", "success", "support tools", "tool", "virology", "virome", "virus classification", "virus resource" ], "approved": true } } ], "meta": { "pagination": { "page": 1385, "pages": 1424, "count": 14236 } } }